Skip to main content

Xenon Pharmaceuticals Inc. (XENE)

NASDAQ: XENE · IEX Real-Time Price · USD
24.76 -1.12 (-4.33%)
Dec 3, 2021 4:00 PM EST - Market closed
Market Cap1.34B
Revenue (ttm)19.85M
Net Income (ttm)-63.99M
Shares Out53.92M
EPS (ttm)-1.66
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,661,671
Open26.45
Previous Close25.88
Day's Range23.46 - 27.00
52-Week Range10.86 - 36.42
Beta1.84
AnalystsStrong Buy
Price Target45.33 (+83.1%)
Earnings DateNov 10, 2021

About XENE

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel modulator that is Phase III clinical trials for the treatment of KCNQ2 epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel modulator, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a select...

IndustryBiotechnology
IPO DateNov 5, 2014
CEOSimon Pimstone
Employees123
Stock ExchangeNASDAQ
Ticker SymbolXENE
Full Company Profile

Financial Performance

In 2020, XENE's revenue was $32.17 million, an increase of 371.02% compared to the previous year's $6.83 million. Losses were -$28.84 million, -30.67% less than in 2019.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for XENE stock is "Strong Buy." The 12-month stock price forecast is 45.33, which is an increase of 83.08% from the latest price.

Price Target
$45.33
(83.08% upside)
Analyst Consensus: Strong Buy

News

Xenon Stock Jumps On New Encouraging Data From Epilepsy Treatment

Xenon Pharmaceuticals Inc (NASDAQ: XENE) announced additional positive data from new sub-analyses of Phase 2b X-TOLE trial of XEN1101 in adult patients with focal epilepsy. The Data will be presented at...

1 day ago - Benzinga

Xenon Pharmaceuticals Presents Additional Positive Data from Phase 2b ‘X-TOLE' Clinical Trial at the Annual Meeting o...

Topline Data Showed All Primary and Secondary Seizure Reduction Endpoints Statistically Significant Across All Dose Groups, with p-value of

1 day ago - GlobeNewsWire

Xenon Pharmaceuticals Provides Updates on Proprietary Neurology Pipeline Programs at the Annual Meeting of the Americ...

BURNABY, British Columbia, Dec. 03, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that it will provide updates on its ...

1 day ago - GlobeNewsWire

Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences

BURNABY, British Columbia, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that Ian Mortimer, Xenon's President...

3 weeks ago - GlobeNewsWire

Xenon Pharmaceuticals (XENE) Reports Q3 Loss, Tops Revenue Estimates

Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of 18.18% and 4.69%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

3 weeks ago - Zacks Investment Research

Xenon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update

XEN1101 X-TOLE Presentations Scheduled at AES 2021 with Planning Underway for Phase 3 Initiation in 2022

3 weeks ago - GlobeNewsWire

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Third Quarter 2021 Financial Results and Provi...

BURNABY, British Columbia, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its third quarter 202...

1 month ago - GlobeNewsWire

Xenon Pharmaceuticals Has a Great Story But Too High a Price

XENE stock is a valuable stock market lesson about separating great expectations for stocks from the company's true fundamentals. The post Xenon Pharmaceuticals Has a Great Story But Too High a Price ap...

1 month ago - InvestorPlace

Earnings Preview: Xenon Pharmaceuticals (XENE) Q3 Earnings Expected to Decline

Xenon Pharmaceuticals (XENE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Xenon: Heading Toward Phase III With Strong Momentum

Xenon just delivered strong clinical trial results and leveraged that into a strong fundraising effort. That has XENE stock in a good place going forward.

1 month ago - InvestorPlace

New Clinical Results Make Xenon Pharmaceuticals' Stock Worthy Again

XENE stock deserved to move higher but was stuck for months -- until a game-changing epilepsy treatment put Xenon in the spotlight again. The post New Clinical Results Make Xenon Pharmaceuticals' Stock ...

1 month ago - InvestorPlace

Shares of Xenon Pharmaceuticals Inc. Have Risen Above Previous 52-Week High

Shares of Xenon Pharmaceuticals Inc . (NASDAQ: XENE) traded at a new 52-week high today of $34.80.

1 month ago - Benzinga

3 Growth Stocks Near 52-Week Highs to Buy Anyway

These top performers have what it takes to keep providing outsized gains for patient investors.

Other symbols:ALNYPANW
1 month ago - The Motley Fool

Xenon Pharmaceuticals Announces Closing of $345 Million Public Offering Including Full Exercise of the Underwriters' ...

BURNABY, British Columbia, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced the closing of its previously announced...

1 month ago - GlobeNewsWire

Xenon Pharmaceuticals Raises $300M Via Equity

Xenon Pharmaceuticals Inc (NASDAQ: XENE) priced its underwritten public offering of 8.5 million shares and pre-funded warrants to purchase up to 1.7 million shares. The common share offer price of $29.5...

1 month ago - Benzinga

Xenon Pharmaceuticals Announces Pricing of $300.0 Million Public Offering

BURNABY, British Columbia, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced the pricing of its underwritten public ...

1 month ago - GlobeNewsWire

Is Xenon Pharmaceuticals a Good Stock to Buy Now?

Despite the big run-up yesterday, there could be enough fuel to push this biotech stock even higher.

1 month ago - The Motley Fool

Xenon Pharmaceuticals Announces Proposed Public Offering

BURNABY, British Columbia, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a clinical stage biopharmaceutical company, today announced that it has commenced an underwritten ...

1 month ago - GlobeNewsWire

XENE Stock: The Huge FDA News Sending Xenon Pharmaceuticals to the Moon

Here's why investors in clinical-stage biotech stock Xenon Pharmaceuticals are cheering today as XENE stock runs wild. The post XENE Stock: The Huge FDA News Sending Xenon Pharmaceuticals to the Moon ap...

1 month ago - InvestorPlace

Xenon Pharma Shares Jump After Epilepsy Treatment Phase 2 Data Meets Primary Endpoint

Xenon Pharmaceuticals Inc (NASDAQ: XENE) has reported topline results from the Phase 2b X-TOLE trial evaluating XEN1101 as an adjunctive treatment in adult patients with focal epilepsy. The trial met it...

2 months ago - Benzinga

Why Xenon Pharmaceuticals Stock Is Soaring Today

Xenon Pharmaceuticals Inc (NASDAQ: XENE) is trading significantly higher Monday after the company announced its phase 2 study of XEN1101 for the treatment of epilepsy met all primary and secondary endpo...

2 months ago - Benzinga

Tesla Sets Delivery Records, but This Nasdaq Stock Was the Big Premarket Winner Monday

Markets are looking to open on a down note.

Other symbols:TSLA
2 months ago - The Motley Fool

Why Xenon Pharmaceuticals Stock Is Screaming Higher Today

A positive mid-stage trial is powering this biotech stock higher today.

2 months ago - The Motley Fool

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Topline Results from Phase 2b ‘X-TOLE' Clinica...

BURNABY, British Columbia, Oct. 03, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that Xenon management will host a co...

2 months ago - GlobeNewsWire

Are Options Traders Betting on a Big Move in Xenon (XENE) Stock?

Investors need to pay close attention to Xenon (XENE) stock based on the movements in the options market lately.

2 months ago - Zacks Investment Research